Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors

NCT01007032 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01007032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01007032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2009
Completion date
April 30, 2015
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tumors